Literature DB >> 23083877

Does partial nephrectomy result in a durable overall survival benefit in the Medicare population?

Marc C Smaldone1, Brian Egleston, Robert G Uzzo, Alexander Kutikov.   

Abstract

PURPOSE: We assessed whether the impact of partial nephrectomy and radical nephrectomy on overall mortality differed by patient age in a Medicare population undergoing surgery for T1a renal cell carcinoma.
MATERIALS AND METHODS: Using linked SEER (Surveillance, Epidemiology and End Results)-Medicare data, we identified patients older than 66 years who underwent partial nephrectomy or radical nephrectomy for T1a (4 cm or smaller) renal cell carcinoma from 1995 to 2007. The effects of procedure type on overall mortality by age were assessed using time dependent Cox proportional hazards models adjusted by propensity score based weighting.
RESULTS: A total of 5,496 patients (mean age 74.2 ± 5.6 years, 55.9% male) who underwent partial nephrectomy (1,665; 30.3%) or radical nephrectomy (3,831; 69.7%) for 4 cm or smaller renal cell carcinoma (mean tumor size 2.8 ± 0.9 cm) were identified. After adjustment, a statistically significant survival benefit for partial nephrectomy compared to radical nephrectomy was observed at 1 year (age 68, HR 1.6, CI 1.2-2.3; age 75, HR 1.5, CI 1.1-1.9; age 85, HR 1.7, CI 1.1-2.5) and 3 years (age 68, HR 1.4, CI 1.03-2.0; age 75, HR 1.3, CI 1.1-1.6; age 85, HR 1.5, CI 1.02-2.3), while these trends became insignificant in patients younger than 68 and older than 85 years. However, the survival benefit decreased with time, and little significant benefit with partial nephrectomy was observed at 5 and 10 years after surgery regardless of age (66 years or older).
CONCLUSIONS: Lacking strong evidence regarding a long-term survival benefit, the decision to perform partial nephrectomy in elderly patients should be individualized, and placed in the context of baseline renal function, expected surgical morbidity and competing risks to survival.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23083877      PMCID: PMC3815608          DOI: 10.1016/j.juro.2012.07.099

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  28 in total

1.  Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study.

Authors:  Jared K Lunceford; Marie Davidian
Journal:  Stat Med       Date:  2004-10-15       Impact factor: 2.373

2.  Adverse effects of androgen deprivation and the limits of national tumor registries.

Authors:  Matthew R Cooperberg
Journal:  Eur Urol       Date:  2011-11-30       Impact factor: 20.096

3.  Breast cancer adjuvant therapy: time to consider its time-dependent effects.

Authors:  Ismail Jatoi; William F Anderson; Jong-Hyeon Jeong; Carol K Redmond
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

5.  Objective measures of renal mass anatomic complexity predict rates of major complications following partial nephrectomy.

Authors:  Jay Simhan; Marc C Smaldone; Kevin J Tsai; Daniel J Canter; Tianyu Li; Alexander Kutikov; Rosalia Viterbo; David Y T Chen; Richard E Greenberg; Robert G Uzzo
Journal:  Eur Urol       Date:  2011-05-25       Impact factor: 20.096

6.  Rising incidence of small renal masses: a need to reassess treatment effect.

Authors:  John M Hollingsworth; David C Miller; Stephanie Daignault; Brent K Hollenbeck
Journal:  J Natl Cancer Inst       Date:  2006-09-20       Impact factor: 13.506

7.  Trends in renal tumor surgery delivery within the United States.

Authors:  Lori M Dulabon; William T Lowrance; Paul Russo; William C Huang
Journal:  Cancer       Date:  2010-05-15       Impact factor: 6.860

8.  National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization?

Authors:  Brent K Hollenbeck; David A Taub; David C Miller; Rodney L Dunn; John T Wei
Journal:  Urology       Date:  2006-01-25       Impact factor: 2.649

9.  Limits of observational data in determining outcomes from cancer therapy.

Authors:  Sharon H Giordano; Yong-Fang Kuo; Zhigang Duan; Gabriel N Hortobagyi; Jean Freeman; James S Goodwin
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

10.  Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes?

Authors:  William C Huang; Elena B Elkin; Andrew S Levey; Thomas L Jang; Paul Russo
Journal:  J Urol       Date:  2008-11-13       Impact factor: 7.450

View more
  15 in total

1.  Assessing the burden of complications after surgery for clinically localized kidney cancer by age and comorbidity status.

Authors:  Jeffrey J Tomaszewski; Robert G Uzzo; Alexander Kutikov; Katie Hrebinko; Reza Mehrazin; Anthony Corcoran; Serge Ginzburg; Rosalia Viterbo; David Y T Chen; Richard E Greenberg; Marc C Smaldone
Journal:  Urology       Date:  2014-04       Impact factor: 2.649

2.  Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project).

Authors:  Maria C Mir; Nicola Pavan; Umberto Capitanio; Alessandro Antonelli; Ithaar Derweesh; Oscar Rodriguez-Faba; Estefania Linares; Toshio Takagi; Koon H Rha; Christian Fiori; Tobias Maurer; Chao Zang; Alexandre Mottrie; Paolo Umari; Jean-Alexandre Long; Gaelle Fiard; Cosimo De Nunzio; Andrea Tubaro; Andrew T Tracey; Matteo Ferro; Ottavio De Cobelli; Salvatore Micali; Luigi Bevilacqua; João Torres; Luigi Schips; Roberto Castellucci; Ryan Dobbs; Giuseppe Quarto; Pierluigi Bove; Antonio Celia; Bernardino De Concilio; Carlo Trombetta; Tommaso Silvestri; Alessandro Larcher; Francesco Montorsi; Carlotta Palumbo; Maria Furlan; Ahmet Bindayi; Zachary Hamilton; Alberto Breda; Joan Palou; Alfredo Aguilera; Kazunari Tanabe; Ali Raheem; Thomas Amiel; Bo Yang; Estevão Lima; Simone Crivellaro; Sisto Perdona; Caterina Gregorio; Giulia Barbati; Francesco Porpiglia; Riccardo Autorino
Journal:  World J Urol       Date:  2019-04-01       Impact factor: 4.226

3.  Kidney cancer: Emerging guidelines for managing small renal masses.

Authors:  Benjamin T Ristau; Marc C Smaldone
Journal:  Nat Rev Urol       Date:  2017-03-14       Impact factor: 14.432

Review 4.  Trends in surgical management of T1 renal cell carcinoma.

Authors:  Jonas Schiffmann; Marco Bianchi; Maxine Sun; Andreas Becker
Journal:  Curr Urol Rep       Date:  2014-02       Impact factor: 3.092

Review 5.  Risk of chronic kidney disease after cancer nephrectomy.

Authors:  Lin Li; Wei Ling Lau; Connie M Rhee; Kevin Harley; Csaba P Kovesdy; John J Sim; Steve Jacobsen; Anthony Chang; Jaime Landman; Kamyar Kalantar-Zadeh
Journal:  Nat Rev Nephrol       Date:  2014-01-14       Impact factor: 28.314

6.  Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma.

Authors:  Jay Simhan; Marc C Smaldone; Brian L Egleston; Daniel Canter; Steven N Sterious; Anthony T Corcoran; Serge Ginzburg; Robert G Uzzo; Alexander Kutikov
Journal:  BJU Int       Date:  2014-04-03       Impact factor: 5.588

7.  Prediction of significant estimated glomerular filtration rate decline after renal unit removal to aid in the clinical choice between radical and partial nephrectomy in patients with a renal mass and normal renal function.

Authors:  Andrew G McIntosh; Daniel C Parker; Brian L Egleston; Robert G Uzzo; Mohammed Haseebuddin; Shreyas S Joshi; Rosalia Viterbo; Richard E Greenberg; David Y T Chen; Marc C Smaldone; Alexander Kutikov
Journal:  BJU Int       Date:  2019-06-30       Impact factor: 5.588

Review 8.  Oncological and renal medical importance of kidney-sparing surgery.

Authors:  Paul Russo
Journal:  Nat Rev Urol       Date:  2013-03-05       Impact factor: 14.432

9.  Clinical characteristics associated with treatment type for localized renal tumors: implications for practice pattern assessment.

Authors:  Marc C Smaldone; Gauthami Churukanti; Jay Simhan; Simon P Kim; Jose Reyes; Fang Zhu; Alexander Kutikov; Rosalia Viterbo; David Y T Chen; Richard E Greenberg; Robert G Uzzo
Journal:  Urology       Date:  2013-02       Impact factor: 2.649

Review 10.  Active surveillance of small renal masses.

Authors:  Marc C Smaldone; Anthony T Corcoran; Robert G Uzzo
Journal:  Nat Rev Urol       Date:  2013-04-09       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.